AEMD ▲ +100.7% - Aethlon Medical, Inc.
$AEMD AEMD NRTX - Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis
Aethlon Medical shares surged 100.7% following news of a merger with North Immunology to advance a bispecific antibody candidate targeting atopic dermatitis, a prevalent inflammatory skin condition. The combination aims to accelerate development of the IL-13 x IL-18 bispecific antibody program, which investors viewed as a significant value-creation opportunity for the merged entity.
17-SEP-2026 06:30 AM ET
Share this post
More filings for $AEMD
View full $AEMD filing history →💬 Comments
Loading comments…
Leave a comment
